Valence ロゴ
人気
ログイン

ウォッチリストに追加

Oragenics Inc.

NYSE American: OGEN · リアルタイム株価 · USD
0.55
+0.01 (1.85%)
終値時点： Aug 18, 2026, 3:59 PM

Oragenics Inc. (OGEN) Stock Price, Analysis & Data

1.85%
買気配n/a
時価総額2.46M
売上高（TTM）n/a
純利益（TTM）-10.08M
ベータn/a
EPS（TTM）-1.45
PER（TTM）n/a
予想PER-0.05
PBR（TTM）0.39
PSR（TTM）n/a
Earnings Daten/a
売気配n/a
出来高38,993
平均出来高（20日）38,916
始値0.54
前日終値0.54
当日レンジ0.53 - 0.56
52週レンジ0.48 - 1.45
アナリストn/a
目標株価n/a
配当n/a
権利落ち日n/a

OGENについて

Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene ampli...

[続きを読む]
業種 Biotechnology
セクター Healthcare
IPO日 Feb 25, 2004
従業員数 3
上場取引所 NYSE American
ティッカー OGEN
ウェブサイト https://www.oragenics.com
企業情報の全文

業績

2025年のOragenicsの売上高は0で、前年の0からundefined%の増加でした。 利益は-9.84Mで、-6.86%の減少でした。

財務諸表

決算サプライズ

OragenicsはMay 12, 2023に四半期決算を発表しました：
  • 売上高は $0 で、予想を下回りました $0, うち NaN% の前年比増加にあたります.
  • EPSは -42.3 で、予想を上回りました 47.71, うち 53.01% の前年比増加にあたります.
    news image

    6か月前 · TipRanks

    Oragenics previews targeted milestones for 2026

    Oragenics (OGEN) previewed its targeted milestones for 2026. Oragenics is advancing its lead candidate ONP-002, a novel intranasal neurosteroid, through clinical studies as the potential first and onl...

    news image

    6か月前 · TipRanks

    Oragenics partners with Duck Flats Pharma to support FDA IND trial design

    Oragenics (OGEN) announced it has engaged Duck Flats Pharma as its U.S. Investigational New Drug, IND, readiness and regulatory execution partner to support FDA-facing preparation and clinical trial d...

    news image

    9か月前 · Associated Press Finance

    Oragenics: Q3 Earnings Snapshot

    SARASOTA, Fla. AP) — Oragenics Inc. OGEN) on Friday reported a loss of $3.1 million in its third quarter.

    news image

    10か月前 · Pharmaceutical Technology

    Oragenics partners Receptor.AI for brain health candidate portfolio

    The partnership will harness AI modelling techniques to determine the ideal receptor binding profiles for new compounds.